Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I studyopen access
- Authors
- Yu, Kyung-Sang; Kim, Byungwook; Shin, Dongseong; Park, Min Kyu; Hwang, Jun Gi; Kim, Min-Gul; Chung, Hyewon; Ghim, JongLyul; Chung, Jae-Yong; Smolen, Josef S.; Burmester, Gerd R.; Kim, SungHyun; Bae, YunJu; Jeon, DaBee; Yoo, JaeKyoung; Yang, GoEun; Bae, JiHun; Keystone, Edward
- Issue Date
- May-2023
- Publisher
- TAYLOR & FRANCIS LTD
- Keywords
- Biosimilar; CT-P47; immunogenicity; pharmacokinetics; safety; tocilizumab
- Citation
- EXPERT OPINION ON INVESTIGATIONAL DRUGS, v.32, no.5, pp.429 - 439
- Journal Title
- EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Volume
- 32
- Number
- 5
- Start Page
- 429
- End Page
- 439
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/88379
- DOI
- 10.1080/13543784.2023.2212155
- ISSN
- 1354-3784
- Abstract
- Background: CT-P47 is a candidate tocilizumab biosimilar. This study assessed the pharmacokinetic (PK) equivalence of CT-P47 and European Union-approved reference tocilizumab (EU-tocilizumab) in healthy Asian adults.Research design and methods: This double-blind, multicenter, parallel-group trial randomized healthy adults (1:1) to receive a single (162 mg/0.9 mL) subcutaneous dose of CT-P47 or EU-tocilizumab. The primary endpoint (Part 2) was PK equivalence by area under the concentration - time curve (AUC) from time zero to last quantifiable concentration (AUC(0-last)), AUC from time zero to infinity (AUC(0-inf)), and maximum serum concentration (C-max). PK equivalence was concluded if 90% confidence intervals (CIs) for the ratios of geometric least-squares means (gLSMs) were within the 80-125% equivalence margin. Additional PK endpoints, immunogenicity, and safety were evaluated.Results: In Part 2, 289 participants were randomized (146 CT-P47; 143 EU-tocilizumab); 284 received study drug. AUC(0-last), AUC(0-inf), and C-max were equivalent between CT-P47 and EU-tocilizumab: 90% CIs for the ratios of gLSMs were within the 80-125% equivalence margin. Secondary PK endpoints, immunogenicity, and safety were comparable between groups.Conclusions: CT-P47 demonstrated PK equivalence with EU-tocilizumab and was well tolerated, following a single dose in healthy adults.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의예과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/88379)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.